Sustiva (efavirenz) is approved.

  • Enid Vázquez
  • Published 1998 in
    Positively aware : the monthly journal of the…

Abstract

A non-nucleoside reverse transcriptase inhibitor, Sustiva (efavirenz, formerly DMP 266), received FDA approval for use by children and adults. Dosing is recommended at bedtime to avert side effects, which are described. People who receive the drug should avoid driving. Women should not become pregnant while taking this medication. Triple combination therapy with Sustiva and AZT/ Epivir (3TC) may be as effective as the combination of Crixivan with AZT/Epivir (3TC), preliminary trials showed. The drug costs about $4,000 a year. Contact information for obtaining financial assistance in the purchasing the drug is provided.

Cite this paper

@article{Vzquez1998SustivaI, title={Sustiva (efavirenz) is approved.}, author={Enid V{\'a}zquez}, journal={Positively aware : the monthly journal of the Test Positive Aware Network}, year={1998}, volume={9 6}, pages={17} }